Advancing Tardive Dyskinesia Care from Risk Identification Through Treatment Selection and Care Coordination

home / peer-exchange / advancing-tardive-dyskinesia-care-from-risk-identification-through-treatment-selection-and-care

Panelists discuss how understanding the clinical characteristics and burden of tardive dyskinesia—especially in older adults—can inform the use of VMAT2 inhibitors, highlight ongoing care gaps, and underscore the vital role of pharmacists in optimizing therapeutic strategies and patient outcomes.

Hidden in Plain Sight: Recognizing Signs and Symptoms of Tardive Dyskinesia

EP. 1: Hidden in Plain Sight: Recognizing Signs and Symptoms of Tardive Dyskinesia

Melissa Cloyd, PharmD, BCPS, BCPP, BCGP, DPLA ;Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ;Stephen Saklad, PharmD, BCPP ;Steven Stoner, PharmD, BCPP, FAAPP
June 23rd 2025

Panelists discuss how enhancing the management of tardive dyskinesia in elderly patients involves recognizing subtle clinical signs, addressing mental health stigma, and leveraging the pivotal role of pharmacists in early detection, patient education, and coordinated, compassionate care.

Watch

Understanding the Impact of Tardive Dyskinesia Across Patient Populations

EP. 2: Understanding the Impact of Tardive Dyskinesia Across Patient Populations

Melissa Cloyd, PharmD, BCPS, BCPP, BCGP, DPLA ;Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ;Stephen Saklad, PharmD, BCPP ;Steven Stoner, PharmD, BCPP, FAAPP
June 23rd 2025

Panelists discuss how the progression of undiagnosed or untreated tardive dyskinesia in older adults can severely compromise independence and quality of life, emphasizing the need for early recognition, risk factor management, and a multidisciplinary approach—including pharmacists—to ensure timely, individualized, and balanced treatment.

Watch